iBio, Inc. insiders have been one-way buyers this past year: three people put roughly $98,000 into the stock and nobody sold in open-market trades.
Biggest single buyer: Duran Felipe, CFO, with roughly $50,000. That includes C-suite money, which tends to get the most attention.
Big money check: 55 institutions held IBIO as of Q2 2026, and more funds bought than sold. No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | Banjak Marc | Executive Officer | Buy | 12,500 | $1.64 | $20K | SEC |
| Mar 27, 2026 | Banjak Marc | Executive Officer | Buy | 1,434 | $1.76 | $3K | SEC |
| Mar 23, 2026 | Duran Felipe | CFO | Buy | 24,835 | $2.02 | $50K | SEC |
| Mar 23, 2026 | Brenner Martin | Officer | Buy | 12,336 | $2.02 | $25K | SEC |
| Jan 13, 2025 | Duran Felipe | CFO | Buy | 9,191 | $2.72 | $25K | SEC |
| Jan 13, 2025 | Brenner Martin | Officer | Buy | 9,191 | $2.72 | $25K | SEC |
| Jan 13, 2025 | Banjak Marc | Executive Officer | Buy | 9,191 | $2.72 | $25K | SEC |
| Jan 13, 2025 | Arkowitz David | Director | Buy | 18,382 | $2.72 | $50K | SEC |
| Jan 13, 2025 | Clark William D | Director | Buy | 1,838 | $2.72 | $5K | SEC |
| Jan 13, 2025 | Parada Antonio Bernardino Guimaraes | Director | Buy | 183,823 | $2.72 | $500K | SEC |
| Jan 13, 2025 | Sender Gary | Director | Buy | 9,191 | $2.72 | $25K | SEC |
| Nov 3, 2023 | Brenner Martin | Officer | Sell | 4,881 | $0.27 | $1K | SEC |
| Oct 5, 2023 | Brenner Martin | Officer | Sell | 5,267 | $0.30 | $2K | SEC |
| Oct 3, 2023 | Brenner Martin | Officer | Sell | 4,215 | $0.31 | $1K | SEC |
| Aug 30, 2023 | Brenner Martin | Officer | Sell | 5,011 | $0.31 | $2K | SEC |
In the last 12 months iBio, Inc. insiders made open-market purchases worth about $98,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in IBIO was filed on 2026-03-27.
55 investment managers reported holding IBIO in SEC Form 13F filings for Q2 2026.
No congressional trades in IBIO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).